Related Experiment Video
Updated: Aug 29, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Temporary losartan or captopril in young SHR induces malignant hypertension despite initial normotension
Simona Racasan1, Bruni Hahnel, Dionne M van der Giezen
1Department of Nephrology, University Hospital, Utrecht, The Netherlands.
Background:
Exposure of normotensive rats to angiotensin-converting enzyme (ACE) inhibitors in early life causes hypertrophy of intrarenal arteries. Similar defects have been found in knockout mice lacking angiotensinogen, ACE, or angiotensin II type 1 (AT1) receptors. On the other hand, transient inhibition of the renin-angiotensin system from 2 weeks of age in spontaneously hypertensive rats (SHR), either with ACE inhibitors or with AT1 receptor antagonists partially prevents the increase in blood pressure. However, permanent treatment of SHR from conception onwards with ACE inhibitors completely prevents hypertension. Although these studies demonstrated protection from hypertension-induced changes in the heart and large arteries, renal arteries were not studied and follow-up did not extend beyond 6 months of age. We postulated that while brief exposure to ACE inhibitors or AT1 receptor antagonists in young SHR would temporarily decrease blood pressure, it would also be associated with development of intrarenal arterial malformation, and ultimately have deleterious effects.
Methods:
Direct effects on intrarenal arterial morphology of an ACE inhibitor (captopril, 100 mg/kg/day) and an AT1 receptor antagonist (losartan, 50 mg/kg/day), administered from the last week of gestation until 8 weeks of age were examined in SHR. After stopping treatment at 8 weeks, we continued to monitor blood pressure until spontaneous death.
Results:
Systolic blood pressure at 8 weeks was normalized by captopril and losartan (SHR control 187 +/- 8 mm Hg; captopril 118 +/- 5 mm Hg; and losartan 120 +/- 9 mm Hg). However, by 30 weeks, blood pressure had increased to control SHR levels. At 4 weeks, the media of renal arteries and arterioles was hypertrophied. Marked smooth muscle cell hyperplasia of cortical arteries resulted in significantly increased wall thickness by 8 weeks, despite similar external diameter. Arterial wall structure was disrupted, with fragmentation of elastic fibers and irregular distribution of collagen type I fibers. After stopping treatment, the rats gradually began to show poor health and all had died by 1 year of age, while all 1-year-old control SHR females were in good health. The cause of morbidity and mortality in the rats treated in early life was clearly malignant hypertension. Severe hypertrophy of renal arterioles was found, as well as cerebral hemorrhage.
Conclusion:
Despite initial normalization of blood pressure interference with the renin-angiotensin system during a crucial stage of development in SHR can initiate marked smooth muscle cell hyperplasia and disruption of the wall structure of the intrarenal arteries. Subsequent progression of this intrarenal process after cessation of treatment suggests an independent process that eventually results in malignant hypertension and early death.
Insights
Early life exposure to ACE inhibitors or AT1 receptor antagonists in rats normalized blood pressure but caused severe intrarenal arterial malformations, leading to malignant hypertension and early death.
Area of Science:
- Cardiovascular Science
- Developmental Biology
- Pharmacology
Background:
- Early life exposure to renin-angiotensin system (RAS) inhibitors can cause intrarenal artery hypertrophy in rats.
- Similar defects are observed in knockout mice lacking key RAS components.
- Transient RAS inhibition in young spontaneously hypertensive rats (SHR) partially prevents hypertension, while permanent inhibition prevents it entirely.
Purpose of the Study:
- To investigate the long-term effects of early-life RAS inhibition on intrarenal arterial morphology and blood pressure in SHR.
- To determine if temporary RAS blockade leads to deleterious outcomes despite initial blood pressure normalization.
Main Methods:
- SHR were treated with an ACE inhibitor (captopril) or an AT1 receptor antagonist (losartan) from late gestation to 8 weeks of age.
- Intrarenal arterial morphology was assessed at 4 and 8 weeks.
- Blood pressure was monitored until spontaneous death after treatment cessation.
Main Results:
- Both captopril and losartan normalized systolic blood pressure at 8 weeks, but levels returned to control SHR levels by 30 weeks.
- Treatment induced significant smooth muscle cell hyperplasia and hypertrophy of renal arteries and arterioles by 8 weeks.
- Arterial walls showed disrupted structure, with fragmented elastic fibers and irregular collagen distribution.
- Treated rats exhibited poor health, succumbing to malignant hypertension and cerebral hemorrhage by 1 year of age.
Conclusions:
- Interference with the RAS during a critical developmental window in SHR initiates intrarenal arterial smooth muscle cell hyperplasia and structural disruption.
- This process continues independently after treatment cessation, leading to malignant hypertension and premature mortality.
- Early-life RAS inhibition, despite initial blood pressure control, has detrimental long-term consequences on renal vasculature and survival in SHR.
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Hypertension and Regulation of Blood Pressure